Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)
Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)
Custom Lucite celebrating the approval by the U.S. Food and Drug Administration (FDA) of the drug Crenessity. Crenessity was developed by Neurocrine Biosciences to treat a rare congenital adrenal condition. (25ALJ020)
Custom Lucite, incorporating an embedded vial of Imdelltra, celebrating the approval of the drug by the Food and Drug Administration (FDA). Developed by Amgen, Imdelltra treats small cell lung cancer, a condition that afflicts about 35,000 Americans annually. (24ALJ148)
Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
Capsule-themed custom crystal commemoratng the first patient dosed stage in the development of ACR-2316. The cancer treatment was developed by Acrivon Therapeutics, a Watertown, Massachusetts-based biopharmaceutical company. (24AKL397)
Crystal commemorative celebrating FDA approval of Ogsiveo, a treatment for desmoid tumors. (24aZH051)
Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Custom Award recognizing contributions to the development of a medical implant, and embedding the actual device within Lucite. (23AZH106)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
